Qualifying Therapeutic Discovery Project Program

Qualifying Therapeutic Discovery Project Program

The Qualifying Therapeutic Discovery Project Program was established under the US Patient Protection and Affordable Care Act in 2009, providing a competitive tax credit for small biotech companies investing in therapeutic discovery. The program targets firms with fewer than 250 employees, focusing on projects that show potential for new therapies in areas like cancer, rare diseases, and neurological disorders. Strategy involves assessing applications based on scientific merit and potential for health impact, with awards up to $5 million for qualified expenses. The program has supported hundreds of companies across the US, with notable investments including Aeterna Zentaris (per SEC filings, 2011) and Cytori Therapeutics (per public records). Geographic coverage spans major biotech hubs including San Francisco, Boston, and New York, as well as select European locations. The program does not disclose AUM or total deployment figures publicly. It operates as a project-based award system rather than a traditional investment fund, with awards recorded by the IRS. No recent operational events are publicly available beyond the program's initial rollout and subsequent extensions. A structural differentiator is its government-backed funding model — the program does not take equity or seek returns, but rather provides non-dilutive capital to de-risk early-stage therapeutic projects. This makes it a unique source of funding for small biotech firms.